List view / Grid view
31 August 2013 | By Pfizer
Results presented at the ESC Congress 2013...
30 August 2013 | By Sanofi
Sanofi and its subsidiary Genzyme announced that the European Commission has granted marketing authorization for Aubagio® (teriflunomide)...
30 August 2013 | By Teva Pharmaceutical Industries Ltd
TEVA announced top-line results of its final Phase III clinical study for armodafinil (NUVIGIL®)...
30 August 2013 | By Abbott
Analysis of more than 1 million adult hospital cases revealed 21 percent reduction in length of hospital stay and cost with nutritional intervention...
29 August 2013 | By Daiichi Sankyo
Daiichi Sankyo has filed an application for approval in Japan to manufacture and market RANMARK®...
29 August 2013 | By Sanofi
Sanofi announces that it has successfully priced its offering of EUR 1 billion of notes, due 2020, bearing interest at an annual rate of 1.875%...
28 August 2013 | By IMBA - Institute of Molecular Biotechnology GmbH
Complex human brain tissue has been successfully developed in a three-dimensional culture system established in an Austrian laboratory...
28 August 2013 | By Carbon Trust
ABPI collaborates with the Carbon Trust to help pharmaceutical companies quickly estimate the carbon footprint of tablet medicines distributed in blister packs...
27 August 2013 | By Amgen
Amgen will present new data on omecamtiv mecarbil, a small molecule cardiac myosin activator that is being studied for the treatment of heart failure in collaboration with Cytokinetics...
26 August 2013 | By Boehringer Ingelheim
Boehringer Ingelheim announced the upcoming presentation of new data on the novel oral anticoagulant (NOAC) Pradaxa® (dabigatran etexilate) during the ESC Congress 2013...
26 August 2013 | By Sanofi Pasteur
“We are pleased that this study demonstrates the superior relative efficacy of Fluzone High-Dose vaccine..."
26 August 2013 | By Novartis
Novartis has invited 60 selected students from leading international universities in 21 countries to its headquarters in Switzerland for the International Biotechnology Leadership Camp...
26 August 2013 | By AstraZeneca
AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into a definitive agreement to acquire Amplimmune...
25 August 2013 | By Amgen
Amgen will acquire all of the outstanding shares of Onyx for $125 per share in cash...
23 August 2013 | By GlaxoSmithKline
The first of four Phase III studies, the SHIELD-1 study, investigating vercirnon in adult patients with moderately-to-severely active Crohn’s disease did not achieve the primary endpoint...
